Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells

Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) are caused by inactivating mutations in TSC1 or TSC2, leading to mTORC1 hyperactivation. The mTORC1 inhibitors rapamycin and analogs (rapalogs) are approved for treating of TSC and LAM. Due to their cytostatic and not cytocidal acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Valianou, Matthildi, Filippidou, Natalia, Johnson, Daniel L., Vogel, Peter, Zhang, Erik Y., Liu, Xiaolei, Lu, Yiyang, Yu, Jane J., Bissler, John J., Astrinidis, Aristotelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395747/
https://www.ncbi.nlm.nih.gov/pubmed/30816188
http://dx.doi.org/10.1038/s41598-019-39418-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395747/
https://www.ncbi.nlm.nih.gov/pubmed/30816188
http://dx.doi.org/10.1038/s41598-019-39418-5

Ejemplares similares